Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Hubei Center for Adverse Drug Reaction Monitoring, Wuhan, 430030, China.
Curr Med Sci. 2021 Aug;41(4):827-831. doi: 10.1007/s11596-021-2387-1. Epub 2021 Aug 17.
The characteristics of oxaliplatin-induced hypersensitivity reactions (HSRs) in Chinese patients were investigated to provide a reference for patients treated with oxaliplatin.
The study reviewed the records of patients who developed oxaliplatin-induced HSRs in 17 hospitals from May 2016 to May 2017. We collected and analyzed the basic information, history of oxaliplatin administration and premedication treatments, chemotherapy cycles, HSR symptoms, and the management and outcomes of these patients.
Oxaliplatin-induced HSRs were recorded in 137 patients who had been treated with oxaliplatin-containing regimens. Five different chemotherapy regimens were applied. The median infusion cycle when oxaliplatin-induced HSRs occurred was 7, and HSRs occurred during or shortly after oxaliplatin infusion. Most of the patients experienced grade 1 or grade 2 HSRs with mild symptoms of pruritis (49.64%), flushing (46.72%), chest discomfort (26.28%), and urticaria (25.55%). The majority of the patients completely recovered from HSRs following treatment with antihistamines and dexamethasone. Seven patients completed chemotherapy with oxaliplatin after the symptoms resolved with proper management.
The results indicate that oxaliplatin-induced HSRs remain an important issue in safely and successfully fulfilling oxaliplatin-containing chemotherapy. Further studies are needed to analyze the risk factors and establish prophylaxis for such reactions.
研究中国患者奥沙利铂诱导的过敏反应(HSR)的特征,为奥沙利铂治疗患者提供参考。
本研究回顾了 2016 年 5 月至 2017 年 5 月 17 家医院接受奥沙利铂诱导 HSR 的患者的记录。我们收集并分析了患者的基本信息、奥沙利铂给药和预处理治疗史、化疗周期、HSR 症状以及这些患者的治疗和结局。
137 例接受含奥沙利铂方案治疗的患者记录了奥沙利铂诱导的 HSR。应用了五种不同的化疗方案。发生奥沙利铂诱导的 HSR 时的中位输注周期为 7,HSR 发生在奥沙利铂输注期间或输注后不久。大多数患者出现 1 级或 2 级 HSR,症状轻微,表现为瘙痒(49.64%)、潮红(46.72%)、胸部不适(26.28%)和荨麻疹(25.55%)。大多数患者在接受抗组胺药和地塞米松治疗后完全从 HSR 中恢复。7 例患者在症状缓解后完成了奥沙利铂化疗。
结果表明,奥沙利铂诱导的 HSR 仍然是安全、成功完成含奥沙利铂化疗的重要问题。需要进一步研究分析这些反应的危险因素,并制定预防措施。